CART Cell Therapy and Emerging Bispecifics for the Treatment of Follicular Lymphoma

Sairah Ahmed MD Department of Lymphoma/Myeloma and Dept of Stem Cell Transplant and Cellular Therapy Clinical Director CART program – Lymphoma/Myeloma MD Anderson Cancer Center





Disclosures

Research support: (paid to my institution)

- Tessa Therapeutics, SeaGen, Merck, Xencor

Advisory committee member:


- Sanofi, SeaGen, Tessa Therapeutics

Consultancy:

Novartis, Myeloid Therapeutics, Servier

Follicular lymphoma is characterized by recurrent relapses but not all FL is the same


- Survival for patients with follicular lymphoma has improved considerably with incorporation of anti-CD20 antibodies and chemotherapy or more recently, immunomodulatory agents like lenalidomide
- These approaches yield overall response rates of more than 90%, and nearly half of patients remain alive without progression at 10 years
- Life expectancy of FL patients in CR30 is similar to general population but shorter for non-CR30
- Early relapse denotes a significantly poorer survival and defines a *High-Risk* group needing better therapies




Disease Response Changes By Line of Therapy

 As the disease recurs, patients are treated with multiple lines of therapies during their lifetime

 However response to therapy decreases with subsequent lines as does overall survival



Line 0	Line 1	Line 2		-ine 3
Observation or non-systemic tr	eatment	erapy 📃 Non-novel mor	notherapy	Non-novel monotherapy
	Anti-CD20 monothe	erapy Anti-CD20 mor	notherapy	Anti-CD20 monotherapy
i-CD20 CHOP ± itional agents			Anti-CD20 CHOP	± additional agents Anti addi
i-CD20 CVP ± itional agents		Anti-CD20 CHOP ± additional agents	Anti-CD20 CVP ±	additional agents
Anti-CD20 be additional age	endamustine ± ents			
+ + Anti-CD20 lei additional ag				Anti-CD20 bendamustine additional agents
Anti-CD20 lenalidomide ± additional agents	Anti-CD20 salvage ± additional agents		Anti-CD20 C	VP ± additional agents
Anti-CD20 salvage ± additional age	Anti-CD20 with novel t	herapy		112
Anti-CD20 with novel therapy				
stine ± Novel me	onotherapy	Novel monotherapy		Anti-CD20 bendamu additional agents
Casulo et al., 🚺 Other co	mbination therapies	Other combination therapies		
el titel apy	munotherapy ± additional agents	Radioimmunotherapy ± additional agents Salvage ± additional agents		Anti-CD20 lenalidom Anti-CD20 salvage ± Anti-CD20 with nove Novel monotherapy
herapies Salvage -	± additional agents			Other combination t
Radioimmunotherapy ± addit	ional agents Other	Other		19




Mosunetuzumab cD3 Mosunetuzumab cD3 Mosunetuzumab cD3	*' <u>\</u>	** 1
B-cell T-cell 0.2 Median PFS 17.9 mo 0.0 2 4 6 8 10 12 14 16 18 Patients Time from the first response (months) at risk 90 80 66 56 55 46 39 35 26 15	20 22 12 10	24 3
lgG1	N=90	
 single agent and combinations Median # of prior lines, n (range) 	3 (2–1	0)
EFS 65%. CRS primarily grade 1-2 (Budde et al. ASH 21 #127) therapy Alkylator	90 (100 90 (100 17 (18.9)%)
 Monotherapy as second-line or greater: with subcutaneous step- up dosing, low CRS rates and ORR 80% in recurrent FL (Bartlett et CAR-T 	13 (14.4 3 (3.3%	4%)
al, ASH 21 #3573) Prior ASCT	19 (21.1	%)
• M+Len in R/R FL as second-line of greater – ORR 92% in 13 pts Refractory to last prior therapy	62 (68.9	9%)
evaluable for efficacy, CMR 77% (Morschhauser et al., ASH 21) Refractory to any prior aCD20 therapy	71 (78.9	9%)
	48 (53.3	3%)
Refractory to prior aCD20 and alkylator (double refractory)	40 (00.0	,,,,

Epcoritamab (SQ dosing)

- Monotherapy and combinations
 - Monotherapy (NCT03625037) DLBCL = 46 FL = 12
 - In FL 80% ORR, 60% CR (dose 12-48 mg)
 - When given at a dose of 0.76 mg or higher, ORR of 90% (95% CI, 55%-100%)
 - among the 10 evaluable patients with RR FL
 - CRS 59%; 0% Grade 3+ CRS

Trial in progress EPCORE NHL-2 phase I/II trial with epcoritamab + R² for R/R CD20+ FL;



All 5 response-evaluable pts achieved an objective response by week 7, with 4 achieving complete metabolic response. CRS 31% (grade 1/2; median time to onset was 15 days, median resolution 2 days (Linton et al., ASH 21 #3535)

19th International Ultmann Chicago Lymphoma Symposium

T-cell proliferation

Perforin/Granzvi

B-induced apoptosis

T cel

Tumor

Epcoritamat

TCR/CD3 complex CD20

Glofitamab

Glofitamab (IV)

- single agent and combinations
 - ORR 81% with monotherapy (n = 53) and 100% with obinutuzumab (n = 19), CRS primarily grade 1/2 (Morschhauser et al, ASH 21 #138)
 - With obinutuzumab (n = 75 with FL): ORR 81%, 69% CR, median duration of CR not reached (Dickinson et al, ASH 21 #2478)
 - CRS rate was 78.9% in the combination cohort and CRS in the monotherapy cohorts was 66% with almost all being grade 1-2




Table: CMR rates with glofitamab as monotherapy or in combination with obinutuzumab by high-risk subgroup

	CMR rate				
Patients n (%)	Glofitamab monotherapy (n=53)	Glofitamab in combination with obinutuzumab (n=19)			
Double-refractory*	8/16 (50%)	3/7 (43%)			
POD24	11/19 (58%)	7/10 (70%)			
PI3Ki-refractory	3/7 (43%)	1/2 (50%)			
SPD ≥3000mm ²	15/24 (63%)	3/7 (43%)			

*Pts refractory to anti-CD20 antibodies and alkylating agents


CMR, complete metabolic response; PI3Ki, phosphoinositide 3-kinase inhibitor; POD24, progression of disease within 24 months of frontline treatment; SPD, sum of the product of the diameters

Odronextamab (IV)


- trials in progress
 - Monotherapy trial with 25 FL pts; CRS rate was 57% (n = 7 with grade ≥ 3)
 - Grade 3 or higher neurotoxicity occurred in two patients
 - The trial was suspended temporarily due to toxicity
 - Responses were evaluated over a broad range of dosages with dosage-dependent responses seen
 - With treatment \geq 80 mg, the FL cohort demonstrated an
 - ORR of 95.5% (CR rate = 77.3%)
 - A global phase II study is currently enrolling 5 separate disease cohorts of rel/ref NHLs, one of which is rel/ref FL

Bannerji R, et al. *Blood.* 2019;134(Suppl_1):762.

Odronextamab bispecific antibody structure



Odronextamab mechanism of action



	N=96
Disease, n	
DLBCL	53
FL Grade 1-3a	25
MCL	6
MZL	6
Other	6
Prior therapies	
Median (range)	3 (1-11) 12 (efficacy analysis)
CAR T therapy, n	6 (safety analysis)
Status at Reporting, n	
Remain on therapy	24
Completed treatment	18
Discontinuation due to PD	54

Conclusions: Bispecific Antibodies

- CD20-CD3 bispecific monotherapy is effective off the shelf therapy for R/R FL
 - Poor-risk Indolent NHL
 - CD20- and alkylating agent-refractory disease
 - PI3K inhibitor-refractory disease
 - history of POD24 months
- CRs have been maintained after completion of therapy
- CRS may reduce with step up dosing and SC administration
- Single-agent and combination studies ongoing

CAR T-cell therapy and bispecific antibodies for R/R FL


	CAR T-Cell Therapy		Bispecifics			
	Axi-cel	Tisa-cel	Glofitamab	Odronextamab	Mosunetuzumab	Epcoritamab
Patient Pop.	R/R FL patients after ≥ 2 prior therapies	R/R FL patients after ≥ 2 prior therapies	R/R NHL patients after ≥ 2 prior therapies	2L+ Indolent B-cell NHL (prior CD20 treatment)	R/R aggressive NHL patients after ≥ 1 prior therapies	Aggressive NHL patients after anti- CD20 treatment and/or ASCT
Trial/Phase	NCT03105336 ZUMA-5, P2	NCT03105336 ELARA, P2	NCT02500407 GO29781, P1/1b	NCT02290951, P1	NCT03075696 NP30179, P1	NCT03625037 P1/2
Efficacy	CR: 80% ORR: 95%	CR: 65% ORR: 83% (ITT population)	CR: 50% ORR: 68%	CR: 75%° ORR: 93%°	CR: 50% ORR: 67%	CR: 60% ORR: 80% (dose ≥ 12 mg)
Safety (Severe AEs)	CRS: 84% (8% grade 3+) Neutropenia: 41% (for all patients with iNHL)	CRS: 48% Grade 3+ Neutropenia: 28% Serious Neurologic Events:10%	CRS: 23% (SAE CRS: 6%) Hypophosphatemia: 23% Neutropenia: 21%	CRS: 62.2% (7.1% grade 3+) Gr 3 neurologic AEs: 4%	CRS: 56.4% Neutropenia: 30.8%	CRS: 59% (Total population); no Grade ≥ 3 CRS events

CAR T vs. Current SOC Treatment for $\geq 3^{rd}$ line FL

Therapy	Axi-cel	Tisa-cel	Copanlisib	Tazemetostat	lbrutinib
Trial	ZUMA-5	ELARA	CHRONOS-1	NCT0189757	NCT01849263.
Ν	84	52	104	42 (EZH2 ^{mut})	110
CR rate	79%	69%	14%	12%	12.5%
PFS at 1 yr	78%	67%	~42%ª	14%	20.4% (2 yr PFS)
Therapy duration	1 mo	1 mo	Until PD	Until PD	Until PD
Reference	Jacobson et al. Lancet Oncol 2022	Fowler et al, Nat Med 2021	Dreyling et al, JCO 2017	Morschhauser et al, Lancet Oncol 2020	Bartlett NL et al, Blood 2018

^aIncludes FL, MZL, SLL, and/or LPL

ELARA Study Design



ELARA CRR Was Consistent Across Subgroups

		1	CRR n/N (%)	[95% CI]
All patients	N=94		62/94 (66.0)	[55.5-75.4]
Age	<65 y (n=70)		46/70 (65.7)	[53.4-76.7]
	≥65 y (n=24)		16/24 (66.7)	[44.7-84.4]
Sex	Female (n=30)		21/30 (70.0)	[50.6-85.3]
	Male (n=64)		41/64 (64.1)	[51.1-75.7]
Number of prior lines of antineoplastic therapy	≤2 lines (n=24)		12/24 (50.0)	[29.1-70.9]
	3-4 lines (n=43)		34/43 (79.1)	[64.0-90.0]
	>4 lines (n=27)		16/27 (59.3)	[38.8-77.6]
PI3K inhibitor use	Pretreated (n=19)	_	15/19 (78.9)	[54.4-93.9]
	Naïve (n=75)		47/75 (62.7)	[50.7-73.6]
Prior HSCT therapy	Yes (n=35)		22/35 (62.9)	[44.9-78.5]
	No (n=59)		40/59 (67.8)	[54.4-79.4]
Disease status to last line of prior antineoplastic therapy	Refractory (n=74)		48/74 (64.9)	[52.9-75.6]
	Relapsed (n=17)		12/17 (70.6)	[44.0-89.7]
POD24 from first-line anti-CD20 mAb containing therapy	Yes (n=58)		32/58 (55.2)	[41.5-68.3]
	No (n=34)		29/34 (85.3)	[68.9-95.0]
CI, confidence interval; CRR, complete response rate; HSCT, hematopoietic stem cell transplant; ORR, overall response rate; PI3K, phosphatidylinositol 3-kinase; POD24, progression of disease within 24 months.	0 10	0 20 30 40 50 60 70 80 90 100		

Presented By: Stephen J. Schuster, MD Stephen.Schuster@pennmedicine.upenn.edu


#ASCO21 | Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.



9

19th International Ultmann Chicago Comphonen Sympositiantion is the property of the author, licensed by ASCO. Permission required for reuse.


ZUMA-5 Study Design



* Patients with stable disease [without relapse] >1 year from completion of last therapy were not eligible.* Single-agent anti-CD20 antibody did not count as line of therapy for eligibility. 1. Cheson 80, et al. J Chin Oncol. 2014;92:5059-3068.

AE, adverse event; aci-col, acicabtagene ciloleucel; CAR, chimeric antigen receptor; CR, complete response; DCR, duration of response; N, follicular lymphome; IKHL, indolent non-Hodgkin lymphome; IRRC, independent: Radiology: Roview Committee; IV, intravenous; mAb, monoclonal antibody; M2L, marginal zone lymphome; GRR, overall response rete; OS, overall survival; PPS, progression-free survival; RR, relapsed/microtory.

Neelapu et al ASH 2021 Abstract 93



Median follow-up of 30.9 months

24-month PFS rate for FL was 63%

No PD events after month 19


ZUMA-5: PFS rates at 24 mo were consistent in key subgroups

	Follicular Lymphoma (n=78) ^a			
Parameter (95% CI)	With POD24 (n=49)	Without POD24 (n=29)		
Median DOR, months	38.6 (14.5–NE)	NR (24.7–NE)		
24-month rate, %	61.1 (44.3–74.3)	72.4 (50.2–85.9)		
Median PFS, months	39.6 (13.1–NE)	NR (25.7–NE)		
24-month rate, %	57.3 (41.2–70.4)	73.0 (51.1–86.2)		
Median OS, months	NR (39.6–NE)	NR (NE–NE)		
24-month rate, %	77.6 (63.1–86.9)	85.9 (66.7–94.5)		
19 th International Ultmann Chicago Lymphoma Symposium		Neelapu et al. ASH 2021; Abstract 93		

Jacobson et al, Lancet Oncol, 2022

19th International Ultmann Chicago Lymphoma Symposium

PFS and OS was significantly higher in ZUMA-5 compared to SCHOLAR-5



0

SCHOLAR-5 is an international, multicenter external control cohort, generated to provide comparative evidence in r/r FL patients meeting ZUMA-5 eligibility criteria with at least 24 months follow up

Patel et al JSMO 2022

Median follow-up time for ZUMA-5 was 23.3 months and for SCHOLAR-5 was 26.2 months

We Don't Talk About Cure




- Lifetime costs for treated FL pts in US is ~\$560k in 2021 how will that change in the future... (Eichten et al, Pharmacoeconomics, 2021)
- New therapies increase the cost of care
- However, addition of rituximab to chemotherapy or R maintenance improved clinical outcomes in a cost-effective manner (Monga et al, Pharmacoeconomics, 2020)
- Can we define "cure" for FL or Should "functional cure" be the goal
- Considerations for time toxicity with "on treatment" and "treatmentfree" periods in FL; how to sequence novel therapies;

ZUMA-22 - Phase 3 study for R/R FL comparing axi-cel to SOC

Designed to determine if axi-cel is superior to SOC as measured by PFS

- Will include FL, grade 1-3a R/R after at least 1 prior line and
 - high-risk disease (POD24)
 OR
 - \geq 2 prior lines
- EXCLUDES Prior CD19 targeted therapy




- How can we better choose individualized "QoL-targeted" treatment? (fixed duration vs ongoing treatment)
- For regimens with similar OS, consider value of PFS benefit vs QoL
 - Is there a benefit for fixed time immunosuppression vs prolonged immunosuppression?
- It is possible that developing "curative" therapies may both improve overall survival for FL but also be cost-effective in the long run and improve QoL



Acknowledgements

THE UNIVERSITY OF TEXAS MDAnderson Cancer Center®


- <u>Department of</u> <u>Lymphoma/Myeloma</u>
 - Sattva Neelapu*
 - Loretta Nastoupil*
 - Jason Westin
 - Michael Green
 - Chris Flowers*
 - Michelle Hildebrandt
 - Paolo Strati
 - Krina Patel
 - *borrowed slides



Thank you! Questions?




Number of Prior Regimens often used to judge suitability for AutoHCT in FL



Rohatiner et al, JCO 2007;25:2554.

Vose et al, BBMT 2008;14:36.

Autologous vs. Allogeneic HCT for ETF Follicular Lymphoma?




				Auto vs	Auto vs	MSD vs
	AutoHCT	MSD	MUD	MSD	MUD	MUD
5-yr PFS	38 (32-45)%	52 (41-62)%	43 (32-54)%	p=0.03	p=0.47	p=0.24
5-yr OS	70 (64-76%)	73 (64-81)%	49 (39-60)%	p=0.60	p<0.0007	p<0.0005



Smith S. & Hamadani M. Cancer. 2018;124:2541-51

Autologous vs. Allogeneic HCT for ETF Follicular Lymphoma?



	AutoHCT	MSD	MUD	Auto vs MSD	Auto vs MUD	MSD vs MUD
5-yr NRM	5 (2-8)%	17 (10-25)%	33 (23-43%)	p=0.003	p<0.0001	p=0.01
5-yr Relapse	58 (52-65)%	31 (21-40)%	23 (14-32)%	p<0.0001	p< 0.001	p=0.25



Smith S. & Hamadani M. Cancer. 2018;124:2541-51